Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 2/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17956516 | 1.00 | JAK2 (0.33) | JAK2JAK1STSL3MBTL1ALDH1A1 | |
| SCHEMBL17956500 | 0.93 | JAK2 (0.33) | JAK2JAK1STSL3MBTL1ALDH1A1 | |
| SCHEMBL20258273 | 0.93 | JAK2 (0.33) | JAK2JAK1STSL3MBTL1ALDH1A1 | |
| SCHEMBL20258281 | 0.92 | JAK2 (0.36) | JAK2JAK1STSL3MBTL1ALDH1A1 | |
| SCHEMBL19409528 | 0.92 | JAK2 (0.36) | JAK2JAK1STSL3MBTL1ALDH1A1 | |
| SCHEMBL17956549 | 0.89 | JAK2 (0.35) | JAK2JAK1STSL3MBTL1TACR1 | |
| SCHEMBL17956521 | 0.88 | JAK2 (0.34) | JAK2JAK1STSL3MBTL1TACR1 | |
| SCHEMBL20258275 | 0.88 | JAK2 (0.34) | JAK2JAK1STSL3MBTL1ALDH1A1 | |
| SCHEMBL20258285 | 0.84 | JAK2 (0.36) | JAK2JAK1STSL3MBTL1ALDH1A1 | |
| SCHEMBL17956498 | 0.84 | JAK2 (0.36) | JAK2JAK1STSL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000491-B2 | Process for producing diazabicyclooctane derivative and intermediate thereof | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000491-B2 | Process for producing diazabicyclooctane derivative and intermediate thereof | CLCN2, ODC1, KCNN4 | JAK2 1743/4885JAK1 3157/4885STS 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.